Full Text:
<2266>
Summary: 
<1654>
CLC number:
On-line Access: 2017-01-03
Received: 2016-08-10
Revision Accepted: 2016-11-09
Crosschecked: 2016-12-16
Cited: 1
Clicked: 3681
Inhibitory effect of Shenqi Fuzheng injection combined with docetaxel on lung cancer cells
| ||||||||||||||
Bo-yu Dong, Cheng Wang, Li Tan, Ning Tan, Meng-di Zhao, Yang Lu, Shou-ying Du. Inhibitory effect of Shenqi Fuzheng injection combined with docetaxel on lung cancer cells[J]. Journal of Zhejiang University Science B, 2017, 18(1): 76-78.
@article{title="Inhibitory effect of Shenqi Fuzheng injection combined with docetaxel on lung cancer cells",
author="Bo-yu Dong, Cheng Wang, Li Tan, Ning Tan, Meng-di Zhao, Yang Lu, Shou-ying Du",
journal="Journal of Zhejiang University Science B",
volume="18",
number="1",
pages="76-78",
year="2017",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1600357"
}
%0 Journal Article
%T Inhibitory effect of Shenqi Fuzheng injection combined with docetaxel on lung cancer cells
%A Bo-yu Dong
%A Cheng Wang
%A Li Tan
%A Ning Tan
%A Meng-di Zhao
%A Yang Lu
%A Shou-ying Du
%J Journal of Zhejiang University SCIENCE B
%V 18
%N 1
%P 76-78
%@ 1673-1581
%D 2017
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1600357
TY - JOUR
T1 - Inhibitory effect of Shenqi Fuzheng injection combined with docetaxel on lung cancer cells
A1 - Bo-yu Dong
A1 - Cheng Wang
A1 - Li Tan
A1 - Ning Tan
A1 - Meng-di Zhao
A1 - Yang Lu
A1 - Shou-ying Du
J0 - Journal of Zhejiang University Science B
VL - 18
IS - 1
SP - 76
EP - 78
%@ 1673-1581
Y1 - 2017
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1600357
Abstract: This study investigated the anticancer effect of Shenqi Fuzheng (SQFZ) injection combined with docetaxel on lung cancer cell lines of A549 and Lewis lung cancer (LLC). SQFZ injection alone cannot inhibit the vitality of lung cancer cells, but the antitumor activity of SQFZ combined with docetaxel was significantly higher than that using docetaxel alone.
[1]Bruno, R., Hille, D., Riva, A., et al., 1998. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J. Clin. Oncol., 16(1):187-196.
[2]Granville, C.A., Dennis, P.A., 2005. An overview of lung cancer genomics and proteomics. Am. J. Respir. Cell Mol. Biol., 32(3):169-176.
[3]Kong, T.D., Liu, D.N., Gao, W.Y., et al., 2014. Effect of Shenqi Fuzheng injection on immune function and quality of life in advanced non-small cell lung cancer patients with palliative treatment. China J. Chin. Med., 29(8):1097-1098 (in Chinese).
[4]Saloustros, E., Mavroudis, D., Georgoulias, V., 2008. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin. Phamacother., 9(15):2603-2616.
[5]Stewart, B.W., Wild, C.P., 2014. The global and regional burden of cancer. In: World Cancer Report 2014. World Health Organization, p.16-54.
[6]Zhang, W.Y., Zhang, W.M., Wang, L., et al., 2011. Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1. China J. Lung Cancer, 14(5):385-390 (in Chinese).
[7]Zhong, M.W., Li, Q.Z., Ye, H.Q., et al., 2015. Clinical observation of shenqi fuzheng injection combing docetaxel and lobaplatin in treatment of old middle-advanced stage lung cancer. Clin. J. Tradit. Chin. Med., 27(5):676-679 (in Chinese).
ORCID: 
Open peer comments: Debate/Discuss/Question/Opinion
<1>